PSA Screening Significantly Lowers Prostate Cancer Death Risk, Cochrane Review Confirms

Prostate-specific antigen (PSA) blood testing is likely to reduce the risk of death from prostate cancer, according to a new review published on Thursday by the Cochrane Collaboration, an influential international research organization. The findings mark a shift in medical evidence that could lead to broader adoption of PSA screening.

The review, led by Juan Franco from Heinrich Heine University Düsseldorf in Germany, concluded with moderate certainty that PSA screening—used to detect elevated PSA levels as a potential indicator of prostate cancer—reduces disease-specific mortality. However, the benefits are modest: an analysis of six major trials involving 800,000 men across Europe and North America found approximately two fewer prostate cancer deaths per 1,000 men screened.

"We have moderate certainty that PSA screening leads to a reduction in prostate cancer deaths," Franco stated during a press conference. "While the benefit is small, it is statistically significant and clinically relevant."

The review’s conclusions challenge previous skepticism about PSA screening’s effectiveness, particularly regarding overdiagnosis and unnecessary treatments. The Cochrane team emphasized that the evidence supports a net benefit when screening is implemented appropriately, though they also noted potential harms, including false positives and psychological distress.

Key findings from the review include:

• PSA screening reduces prostate cancer mortality by about 0.2% per 1,000 men screened.
• Trials were conducted in Europe and North America, covering diverse populations.
• The review assessed data from six large-scale randomized controlled trials.

Experts suggest these findings could influence clinical guidelines and public health policies, particularly in regions where PSA screening is currently underutilized. The Cochrane Collaboration plans to update its recommendations as new evidence emerges.